Neisvac-C

N. meningitidis group C (strain C11) polysaccharide (de‑O‑acetylated) conjugated to tetanus toxoid, the active ingredient in Neisvac‑C, is a vaccine presented as an injectable solution for intramuscular use. It induces immunity that helps prevent invasive disease caused by Neisseria meningitidis serogroup C in at‑risk individuals such as adolescents, travelers and those with complement deficiencies.

GNH USA supplies Neisvac‑C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulatory‑approved batches and cold‑chain logistics for global immunisation programmes.

Neisvac‑C is a conjugate vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup C. - Invasive meningococcal disease (serogroup C): provides active immunity to reduce incidence. - Outbreak control (serogroup C): used in mass vaccination campaigns to halt transmission. - High‑risk groups (e.g., complement deficiency, asplenia, travelers to endemic areas): offers protection against serogroup C infection.

Neisvac‑C is generally well tolerated, but injection‑related and systemic reactions can occur.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache or malaise: general feeling of unease.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare demyelinating neuropathy reported post‑vaccination.

Before administering Neisvac‑C, consider the following precautions. - Contraindication: known hypersensitivity to any vaccine component. - Caution: evaluate for severe immunodeficiency before use. - Pregnancy: safety not established; weigh benefits against potential risks. - Breastfeeding: insufficient data; consider risk‑benefit assessment. - Age: not recommended for children under 2 years unless specifically indicated. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac‑C may interact with other immunizations or immune‑modulating therapies.

Major Interactions (Avoid): - Live attenuated vaccines: avoid administration within 4 weeks before or after Neisvac‑C. - Immunoglobulin therapy: may blunt antibody response if given within 2 weeks of vaccination.

Moderate Interactions (Monitor Closely): - Other inactivated vaccines: can be co‑administered but monitor for increased reactogenicity. - Antipyretics: prophylactic use may reduce immune response; use only if needed. - Corticosteroids: high‑dose therapy may diminish vaccine efficacy.